Please login to the form below

Not currently logged in
Email:
Password:

Juno

This page shows the latest Juno news and features for those working in and with pharma, biotech and healthcare.

Gilead owes BMS millions after losing Yescarta patent infringement trial

Gilead owes BMS millions after losing Yescarta patent infringement trial

The basis of the lawsuit is that Yescarta, which is marketed by Gilead’s Kite Pharma division, infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and the ... Given that Kite independently developed Yescarta and assumed all

Latest news

More from news
Approximately 11 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Celgene and Juno hope to crash the party soon with JCAR017, armed with positive data in diffuse large B-cell lymphoma (DLBCL).

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    $9bn  acquisition of Juno.

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch November 2016 Deal Watch November 2016

    Winding back two years, Juno enjoyed the biggest Nasdaq IPO of 2014 raising around $265m at $24 per share. ... At the end of this November Juno shares were trading at around $20 per share and to date they have not recovered.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma

  • Juno Therapeutics names Cindy Elkins as CIO Juno Therapeutics names Cindy Elkins as CIO

    Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report directly to Hans Bishop, Juno’s president ... She said: “I am delighted to join Juno, a company that reflects my

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics